Core Insights - Silexion Therapeutics Corp. announced new preclinical data showing that SIL204 effectively targets primary and metastatic sites in pancreatic cancer, demonstrating measurable reductions in tumor burden at clinically relevant doses [1][4][5] Group 1: Study Findings - SIL204 was administered subcutaneously in a metastatic pancreatic cancer mouse model, confirming its distribution to key organs and significant reductions in tumor burden across multiple sites [2][5] - A single subcutaneous injection of 5 mg/mouse resulted in statistically significant reductions in tumor burden in the peritoneum, lung, and intestine, with the liver also showing measurable reductions [5] - The study utilized human pancreatic cancer cells with the KRAS G12D mutation, validating the relevance of the dosing for planned clinical use [5] Group 2: Clinical Development Plans - Silexion is on track to initiate Phase 2/3 clinical trials for SIL204 in the first half of 2026, with regulatory submissions planned for Q4 2025 and Q1 2026 [1][9] - The company is expanding tissue culture studies across various cancer types and KRAS mutations to further explore SIL204's potential [8] Group 3: Company Overview - Silexion Therapeutics focuses on developing RNA interference therapies for KRAS-driven cancers, aiming to address the challenges of treating solid tumors with mutated KRAS oncogenes [10]
Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration